1887
  1. Home
  2. Eurosurveillance
  3. Volume 31, Issue 21, 28/May/2026
  4. Article
Surveillance Open Access
Like 0
Download

Abstract

BACKGROUND

Pneumococcal vaccination has been recommended in Germany for adults aged ≥ 60 years (1998) and children aged < 2 years (2006), resulting in a reduction of pneumococcal disease incidence in vaccinated children and unvaccinated individuals through herd protection.

AIM

We aimed to investigate serotype distribution of invasive pneumococcal disease (IPD) among children and adults in 2017–2024.

METHODS

We analysed data of an ongoing nationwide surveillance of IPD. All isolates were serotyped by Neufeld’s Quellung reaction.

RESULTS

In total, 24,122 IPD isolates were analysed by the German Reference Laboratory for Streptococci. Over the study period, case numbers were lower during the COVID-19 pandemic and increased afterwards with higher proportion of pneumococcal conjugate vaccine (PCV)13 serotypes. Serotypes 22F and 33F, included in PCV15 and PCV20, showed only minor variations, whereas PCV20 unique serotypes were less frequently observed in 2022–2024. Serotype 3 persisted in IPD across all age groups, while serotype 4 disappeared in children and adolescents, but increased in adults, most prominently in 18–49-year-olds. Serotype 38 steeply increased in 2023/24, among children aged < 2 years and older adults.

CONCLUSION

The concerning increase of PCV13 serotype IPD in Germany might be related to low vaccination uptake, resulting in inefficient herd protection. The dominance of serotype 3 and the rise of serotype 4 among adults highlight the importance of direct protection and support the current national vaccination recommendation for adults aged ≥ 60 years. The increase in serotype 38 IPD among young children and older adults might indicate a replacement phenomenon, highlighting the importance of IPD serotype surveillance.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.21.2500576
2026-05-28
2026-06-10
/content/10.2807/1560-7917.ES.2026.31.21.2500576
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/21/eurosurv-31-21-4.html?itemId=/content/10.2807/1560-7917.ES.2026.31.21.2500576&mimeType=html&fmt=ahah

References

  1. Hanquet G, Krizova P, Dalby T, Ladhani SN, Nuorti JP, Danis K, et al. Serotype replacement after introduction of 10-valent and 13-valent pneumococcal conjugate vaccines in 10 countries, Europe. Emerg Infect Dis. 2022;28(1):137-8.  https://doi.org/10.3201/eid2801.210734  PMID: 34932457 
  2. Troeger C, Blacker B, Khalil IA, Rao PC, Cao J, Zimsen SRM, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191-210.  https://doi.org/10.1016/S1473-3099(18)30310-4  PMID: 30243584 
  3. Horn EK, Wasserman MD, Hall-Murray C, Sings HL, Chapman R, Farkouh RA. Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges. Expert Rev Vaccines. 2021;20(10):1291-309.  https://doi.org/10.1080/14760584.2021.1971521  PMID: 34424123 
  4. Deloria Knoll M, Bennett JC, Garcia Quesada M, Kagucia EW, Peterson ME, Feikin DR, et al. Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project. Microorganisms. 2021;9(4):742.  https://doi.org/10.3390/microorganisms9040742  PMID: 33918127 
  5. Mitchell AM, Mitchell TJ. Streptococcus pneumoniae: virulence factors and variation. Clin Microbiol Infect. 2010;16(5):411-8.  https://doi.org/10.1111/j.1469-0691.2010.03183.x  PMID: 20132250 
  6. Ganaie FA, Beall BW, Yu J, van der Linden M, McGee L, Satzke C, et al. Update on the evolving landscape of pneumococcal capsule types: new discoveries and way forward. Clin Microbiol Rev. 2025;38(1):e0017524.  https://doi.org/10.1128/cmr.00175-24  PMID: 39878373 
  7. Robert Koch Institut (RKI). Empfehlungen der Ständigen Impfkommission (STIKO) am RKI (Stand Juli 2006):Begründungen zur allgemeinen Empfehlung der Impfung gegen Pneumokokken- und Meningokokken im Säuglings- und Kindesalter. [Recommendations of the Standing Committee on Vaccination (STIKO) at the RKI (as of July 2006): justifications for the general recommendation of vaccination against pneumococcus and meningococcus in infancy and childhood]. German. Epidemiol Bull. 2006; (31):255-60.
  8. Robert Koch Institut (RKI). Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2015. [Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute/Status: August 2015]. German. Epidemiol Bull. 2015; (34):339-40.
  9. Robert Koch Institut (RKI). STIKO: Stellungnahme zum Einsatz von Pneumokokken-Konjugatimpfstoffen im Säuglings-, Kindes- und Jugendalter. [STIKO: Statement on the use of pneumococcal conjugate vaccines in infancy, childhood and adolescence]. German. Epidemiologisches Bulletin.2023;2023(20):3-5.
  10. Robert Koch Institut (RKI). Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut / Stand: März 1998. [Vaccination recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute / Status: March 1998]. German. Epidemiologisches Bulletin.1998;1998(15):101-14.
  11. van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M. Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One. 2015;10(7):e0131494.  https://doi.org/10.1371/journal.pone.0131494  PMID: 26132078 
  12. van der Linden M, Imöhl M, Perniciaro S. Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PLoS One. 2019;14(8):e0220453.  https://doi.org/10.1371/journal.pone.0220453  PMID: 31369597 
  13. Robert Koch Institut (RKI). Epidemiologisches Bulletin. Berlin; RKI: 19 Apr 2018. Available from: https://www.rki.de/DE/Aktuelles/Publikationen/Epidemiologisches-Bulletin/2018/16_18.pdf?__blob=publicationFile&v=1
  14. Robert Koch Institut (RKI). Impfquoten in Deutschland – aktuelle Ergebnisse aus dem RKI-Impfquotenmonitoring. [Vaccination rates in Germany – current results from the RKI vaccination rate monitoring]. German. Epidemiologisches Bulletin.2024;50:3-10.
  15. Poethko-Müller C, Schmitz R. Impfstatus von Erwachsenen in Deutschland Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). [Vaccination coverage in German adults: results of the German health interview and examination survey for adults (DEGS1)]. German. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5-6):845-57.  https://doi.org/10.1007/s00103-013-1693-6  PMID: 23703506 
  16. Perniciaro S, van der Linden M. Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study. Lancet Reg Health Eur. 2021;7:100126.  https://doi.org/10.1016/j.lanepe.2021.100126  PMID: 34557837 
  17. Shaw D, Abad R, Amin-Chowdhury Z, Bautista A, Bennett D, Broughton K, et al. Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium. Lancet Digit Health. 2023;5(9):e582-93.  https://doi.org/10.1016/S2589-7500(23)00108-5  PMID: 37516557 
  18. Brueggemann AB, Jansen van Rensburg MJ, Shaw D, McCarthy ND, Jolley KA, Maiden MCJ, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health. 2021;3(6):e360-70.  https://doi.org/10.1016/S2589-7500(21)00077-7  PMID: 34045002 
  19. Ankert J, Hagel S, Schwarz C, Pan K, Wang L, von Eiff C, et al. Streptococcus pneumoniae re-emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-2, in Germany, 2021. ERJ Open Res. 2023;9(3):00703-02022.  https://doi.org/10.1183/23120541.00703-2022  PMID: 37260459 
  20. Scholz CF, Poulsen K, Kilian M. Novel molecular method for identification of Streptococcus pneumoniae applicable to clinical microbiology and 16S rRNA sequence-based microbiome studies. J Clin Microbiol. 2012;50(6):1968-73.  https://doi.org/10.1128/JCM.00365-12  PMID: 22442329 
  21. Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol. 2006;44(1):124-31.  https://doi.org/10.1128/JCM.44.1.124-131.2006  PMID: 16390959 
  22. Gillespie SH, Ullman C, Smith MD, Emery V. Detection of Streptococcus pneumoniae in sputum samples by PCR. J Clin Microbiol. 1994;32(5):1308-11.  https://doi.org/10.1128/jcm.32.5.1308-1311.1994  PMID: 7914205 
  23. Kawamura Y, Whiley RA, Shu SE, Ezaki T, Hardie JM. Genetic approaches to the identification of the mitis group within the genus Streptococcus. Microbiology (Reading). 1999;145(Pt 9):2605-13.  https://doi.org/10.1099/00221287-145-9-2605  PMID: 10517614 
  24. Wyllie AL, Pannekoek Y, Bovenkerk S, van Engelsdorp Gastelaars J, Ferwerda B, van de Beek D, et al. Sequencing of the variable region of rpsB to discriminate between Streptococcus pneumoniae and other streptococcal species. Open Biol. 2017;7(9):170074.  https://doi.org/10.1098/rsob.170074  PMID: 28931649 
  25. Neufeld F. Über die Agglutination der Pneumokokken und über die Theorie der Agglutination. [On the agglutination of pneumococci and on the theory of agglutination]. German. Med Microbiol Immunol. 1902;34(1):54-72.
  26. Domenech de Celles M, Arduin H, Levy-Bruhl D, Georges S, Souty C, Guillemot D, et al. Unraveling the seasonal epidemiology of pneumococcus. Proc Natl Acad Sci USA. 2019;116(5):1802-7.  https://doi.org/10.1073/pnas.1812388116  PMID: 30642967 
  27. World Health Organization (WHO). Timeline: WHO's COVID-19 response. Geneva: WHO. [Accessed: 13 Apr 2026]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline#
  28. Danino D, Ben-Shimol S, van der Beek BA, Givon-Lavi N, Avni YS, Greenberg D, et al. Decline in pneumococcal disease in young children during the coronavirus disease 2019 (COVID-19) pandemic in Israel associated with suppression of seasonal respiratory viruses, despite persistent pneumococcal carriage: a prospective cohort study. Clin Infect Dis. 2022;75(1):e1154-64.  https://doi.org/10.1093/cid/ciab1014  PMID: 34904635 
  29. Perniciaro S, van der Linden M, Weinberger DM. Reemergence of invasive pneumococcal disease in Germany during the spring and summer of 2021. Clin Infect Dis. 2022;75(7):1149-53.  https://doi.org/10.1093/cid/ciac100  PMID: 35136983 
  30. Bertran M, Amin-Chowdhury Z, Sheppard CL, Eletu S, Zamarreño DV, Ramsay ME, et al. Increased incidence of invasive pneumococcal disease among children after COVID-19 pandemic, England. Emerg Infect Dis. 2022;28(8):1669-72.  https://doi.org/10.3201/eid2808.220304  PMID: 35876698 
  31. Cuypers L, Dambre C, Desmet S. Exceptional high number of IPD cases in winter season 2024-2025 in Belgium in concomitance with rise in vaccine serotypes. Vaccine. 2025;64:127763.  https://doi.org/10.1016/j.vaccine.2025.127763  PMID: 40966978 
  32. Camilli R, Giancristofaro S, Boros S, Bellini B, D’Ambrosio F, Urciuoli R, et al. Invasive pneumococcal diseases before and after the COVID-19 pandemic in Italy (2018-2023). Microorganisms. 2025;13(12):2734.  https://doi.org/10.3390/microorganisms13122734  PMID: 41471938 
  33. Bertran M, D’Aeth JC, Abdullahi F, Eletu S, Andrews NJ, Ramsay ME, et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Lancet Infect Dis. 2024;24(5):546-56.  https://doi.org/10.1016/S1473-3099(23)00706-5  PMID: 38310905 
  34. Centers for Disease Control and Prevention (CDC). ABCs Bact Facts Interactive Data Dashboard. Atlanta: CDC; 21 Aug 2025. Available from: https://www.cdc.gov/abcs/bact-facts/data-dashboard.html
  35. Plainvert C, Varon E, Viriot D, Kempf M, Plainvert C, Alauzet C, et al. Invasive pneumococcal infections in France: Changes from 2009 to 2021 in antibiotic resistance and serotype distribution of Streptococcus pneumoniae based on data from the French Regional Pneumococcal Observatories network. Infect Dis Now. 2023;53(1):104632.  https://doi.org/10.1016/j.idnow.2022.11.001  PMID: 36375765 
  36. Beall B, Walker H, Tran T, Li Z, Varghese J, McGee L, et al. Upsurge of conjugate vaccine serotype 4 invasive pneumococcal disease clusters among adults experiencing homelessness in California, Colorado, and New Mexico. J Infect Dis. 2021;223(7):1241-9.  https://doi.org/10.1093/infdis/jiaa501  PMID: 32798216 
  37. McKee G, Choi A, Madill C, Marriott J, Kibsey P, Hoyano D 2. Outbreak of invasive Streptococcus pneumoniae among an inner-city population in Victoria, British Columbia, 2016-2017. Can Commun Dis Rep. 2018;44(12):317-22.  https://doi.org/10.14745/ccdr.v44i12a02  PMID: 31517952 
  38. Cuypers L, Sanchez GJ, Herrera Avila JP, Naesens R, Antoine-Moussiaux T, Herens S, et al. Rapid increase in serotype 4 invasive pneumococcal disease among vulnerable young male adults in Belgium (2020-2024). Int J Infect Dis. 2026;163:108216.  https://doi.org/10.1016/j.ijid.2025.108216  PMID: 41238171 
  39. Cohen R, Levy C, Ouldali N, Goldrey M, Béchet S, Bonacorsi S, et al. Invasive disease potential of pneumococcal serotypes in children after PCV13 implementation. Clin Infect Dis. 2021;72(8):1453-6.  https://doi.org/10.1093/cid/ciaa917  PMID: 32804200 
  40. Hajji K, Wróbel-Pawelczyk I, van Veldhuizen J, Maruhn K, Miellet WR, Mariman R, et al. Streptococcus pneumoniae serotype 38 emerges as one of the dominant serotypes causing invasive pneumococcal disease in Germany and Poland, but not in the Netherlands. J Infect. 2025;91(1):106519.  https://doi.org/10.1016/j.jinf.2025.106519  PMID: 40436150 
  41. Méroc E, Fletcher MA, Hanquet G, Slack MPE, Baay M, Hayford K, et al. Systematic literature review of the epidemiological characteristics of pneumococcal disease caused by the additional serotypes covered by the 20-valent pneumococcal conjugate vaccine. Microorganisms. 2023;11(7):1816.  https://doi.org/10.3390/microorganisms11071816  PMID: 37512988 
  42. van der Linden M, Itzek A. Vaccination status of children with IPD caused by PCV13 and PCV15 vaccine serotypes, 2011-2024. 43rd Annual The European Society for Paediatric Infectious Diseases (ESPID) meeting; 26–30 May –2025, Bucharest, Romania.
  43. Bahrs C, Kesselmeier M, Kolditz M, Ewig S, Rohde G, Barten-Neiner G, et al. A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany. Eur Respir J. 2022;59(2):2102432.  https://doi.org/10.1183/13993003.02432-2021  PMID: 34824055 
  44. Malley R, Lu YJ, Sebastian S, Zhang F, Willer DO. Multiple antigen presenting system (MAPS): state of the art and potential applications. Expert Rev Vaccines. 2024;23(1):196-204.  https://doi.org/10.1080/14760584.2023.2299384  PMID: 38174559 
  45. Fairman J, Agarwal P, Barbanel S, Behrens C, Berges A, Burky J, et al. Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23). Vaccine. 2021;39(23):3197-206.  https://doi.org/10.1016/j.vaccine.2021.03.070  PMID: 33965258 
Surveillance of invasive pneumococcal disease in Germany: surge in PCV13 serotypes and new challenges, 2017 to 2024
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Mark+PG+van+der+Linden&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van der Linden Mark PG</a>, <a href="/search?value1=Mathias+W+Pletz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pletz Mathias W</a>, <a href="/search?value1=Andreas+Itzek&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Itzek Andreas</a></span>. Surveillance of invasive pneumococcal disease in Germany: surge in PCV13 serotypes and new challenges, 2017 to 2024. <a href="/content/ecdc">Euro Surveill.</a> 2026;31(21):pii=2500576. <a href="https://doi.org/10.2807/1560-7917.ES.2026.31.21.2500576" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2026.31.21.2500576</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 31 Jul 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 18 Dec 2025 </span> </p>
/content/10.2807/1560-7917.ES.2026.31.21.2500576
/content/10.2807/1560-7917.ES.2026.31.21.2500576
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error